Welcome to our dedicated page for Kymera Therapeutics news (Ticker: KYMR), a resource for investors and traders seeking the latest updates and insights on Kymera Therapeutics stock.
Kymera Therapeutics, Inc. (NASDAQ: KYMR) is a clinical-stage biotechnology company advancing a pipeline of oral small molecule degrader medicines based on targeted protein degradation (TPD). This news page aggregates company announcements, clinical updates, collaboration developments and capital markets activity related to Kymera’s work in immunological and other serious diseases.
Readers can follow detailed updates on KT-621, Kymera’s investigational first-in-class oral STAT6 degrader in Phase 2 clinical testing for Type 2 inflammatory diseases such as atopic dermatitis and asthma. News items include Phase 1b and Phase 2 trial progress, biomarker and clinical endpoint data, and regulatory milestones such as U.S. FDA Fast Track designation for moderate to severe atopic dermatitis. Coverage also extends to KT-579, an investigational oral IRF5 degrader for immune-mediated conditions, as it moves from preclinical work toward first-in-human studies.
In addition to internal programs, this feed highlights updates on Kymera’s partnered assets, including the IRAK4 degrader KT-485/SAR447971 in collaboration with Sanofi for immuno-inflammatory diseases and the oral CDK2 molecular glue degrader program with Gilead Sciences for potential use in breast cancer and other solid tumors. Investors can also find information on public offerings of common stock, shelf registration statements, and other corporate events disclosed through press releases and SEC filings.
By reviewing Kymera news on this page, users can track clinical trial milestones, regulatory interactions, collaboration announcements and financing transactions that shape the company’s development trajectory. For those researching KYMR stock or the evolution of targeted protein degradation in immunology and oncology, this consolidated news view provides ongoing context around Kymera’s pipeline and corporate strategy.
Kymera Therapeutics (NASDAQ: KYMR) presented new preclinical data for KT-579, an oral IRF5 degrader, at the American College of Rheumatology Annual Meeting on Oct 27, 2025. The data show disease‑modifying activity across multiple lupus and rheumatoid arthritis models, including reductions in blood interferon‑stimulated genes, serum anti‑dsDNA autoantibodies, kidney IgG deposition, and protection from renal disease progression in lupus models, plus dose‑dependent joint swelling reduction and bone‑protection in RA models. In vitro human assays showed blockade of Th1‑skewing cytokines. The company intends to initiate Phase 1 testing in early 2026.
Kymera Therapeutics (NASDAQ: KYMR) announced late-breaking presentations of positive Phase 1 results for KT-621, their first-in-class oral STAT6 degrader, at two major medical conferences. The Phase 1 healthy volunteer trial demonstrated that KT-621 achieved >90% STAT6 degradation in blood at doses above 1.5 mg and complete degradation in both blood and skin at doses ≥50 mg.
The drug showed impressive biomarker results comparable or superior to dupilumab, with TARC reduction up to 37% and Eotaxin-3 reduction up to 63%. KT-621's BroADen Phase 1b trial in atopic dermatitis patients will report data in Q4 2025, followed by Phase 2b trials in AD and asthma initiating in Q4 2025 and Q1 2026, respectively.
Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company focused on developing oral small molecule degrader medicines, has appointed Brian Adams as Chief Legal Officer and Corporate Secretary. Adams brings nearly two decades of life sciences leadership experience and will oversee the company's legal, governance, and intellectual property functions.
Adams joins from Relay Therapeutics where he served as Chief Legal Officer. His previous experience includes senior roles at Keryx Biopharmaceuticals, Algeta ASA, AVEO Oncology, and Genzyme Corporation. He succeeds Ellen Chiniara, who is retiring to focus on board service and advisory opportunities.
Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company focused on developing oral small molecule degrader medicines for immunological diseases, has announced its participation in four major investor conferences in September 2025.
The company will engage in fireside chats at the Citi Biopharma Back to School Conference (Sept 3), Wells Fargo Healthcare Conference (Sept 4), Morgan Stanley Global Healthcare Conference (Sept 9), and Stifel Virtual Immunology and Inflammation Forum (Sept 15). All presentations will be accessible via live webcast on the company's website, with replays available afterward.
Kymera Therapeutics (NASDAQ: KYMR) reported significant Q2 2025 financial results and pipeline progress. The company announced positive Phase 1 data for KT-621, their oral STAT6 degrader, demonstrating complete STAT6 degradation and favorable safety profile. Kymera secured a strategic partnership with Gilead worth up to $750 million for CDK2 degrader development.
Financial highlights include a strong cash position of $1 billion as of July 31, 2025, extending runway into H2 2028. Q2 2025 showed collaboration revenues of $11.5 million and a net loss of $76.6 million. The company completed a $288 million equity offering in June 2025.
Pipeline developments include advancing KT-621 to Phase 2b trials in atopic dermatitis and asthma starting Q4 2025 and Q1 2026, respectively. KT-579, their IRF5 degrader, is progressing toward Phase 1 trials in early 2026.
Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company focused on developing oral small molecule degrader medicines for immunological diseases, has scheduled its second quarter 2025 financial results announcement for August 11, 2025.
The company will host a video conference call and webcast at 8:30 a.m. ET on the same day. Interested parties can register for the video call and access the webcast through a provided link or by visiting the "News and Events" section in the Investors area of Kymera's website.
Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company, has announced the pricing of a $250.8 million public offering of common stock and pre-funded warrants. The company is offering 5,044,500 shares at $44.00 per share and 655,500 pre-funded warrants at $43.9999 each.
The offering includes a 30-day option for underwriters to purchase up to 855,000 additional shares. The proceeds will support Kymera's pipeline of preclinical and clinical degrader programs. The offering is expected to close on June 30, 2025, with Morgan Stanley, J.P. Morgan, Jefferies, TD Cowen, and Leerink Partners acting as joint book-running managers.
Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company, has announced a proposed public offering of $250.0 million of common stock and pre-funded warrants. The company is also granting underwriters a 30-day option to purchase up to an additional $37.5 million of shares.
The proceeds will be used to advance Kymera's pipeline of preclinical and clinical degrader programs targeting immunological diseases. Morgan Stanley, J.P. Morgan, Jefferies, TD Cowen and Leerink Partners are serving as joint book-running managers for the offering.
Kymera Therapeutics (NASDAQ: KYMR) announced that Sanofi will advance KT-485, their next-generation oral IRAK4 degrader, into clinical testing while discontinuing development of KT-474. KT-485 demonstrated enhanced selectivity, potency, and favorable safety in preclinical testing.
Under their collaboration agreement, Kymera received a $20 million milestone payment in Q2 2025 and remains eligible for up to $975 million in potential milestones, plus double-digit royalties. Kymera maintains the option for a 50/50 development and profit share of KT-485 in the U.S.
Gilead Sciences (NASDAQ: GILD) and Kymera Therapeutics (NASDAQ: KYMR) have entered into an exclusive option and license agreement to develop novel oral molecular glue CDK2 degraders for cancer treatment. The collaboration focuses on developing a new type of drug designed to remove CDK2, a key protein in tumor growth, rather than just inhibiting it.
Under the agreement, Kymera could receive up to $750 million in total payments, including $85 million in upfront and potential option exercise payments, plus tiered royalties ranging from high single-digit to mid-teens on net sales. Kymera will lead research activities, while Gilead will gain global rights upon exercising its option. The deal is expected to impact Gilead's 2025 EPS by approximately $0.02-$0.03.